# Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)

> **NCT00040547** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 29 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Farnesyl Protein Transferase Inhibitor

## Key facts

- **NCT ID:** NCT00040547
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2004-02
- **Final completion:** 2004-02
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2015-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040547, "Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00040547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*